Risks

Long cash-conversion cycle and elevated inventory days versus faster-turn peers can pressure working capital and mute free-cash-flow conversion if demand softens.

Net debt to EBITDA near 2.7x leaves less balance-sheet flexibility than lower-levered specialty-chem peers, increasing sensitivity to cyclical margin compression.

Interest coverage around 7.7x is adequate but below top-tier peers, so higher rates or weaker earnings could constrain capital deployment and pricing resilience.

Receivables collection near 81 days versus leaner distributors and formulators can delay cash realization, amplifying exposure to customer payment slippage in a downturn.

Opportunities

A current ratio above 4.0 and quick ratio above 1.7 provide stronger liquidity than many industrial peers, supporting continuity through demand volatility and input shocks.

Moderate leverage relative to equity can still support disciplined bolt-on growth or share gains versus more stretched peers if end-market conditions remain stable.

Interest coverage above 7x gives more room than highly levered peers to absorb temporary margin pressure, preserving strategic flexibility in pricing and service.

Working-capital intensity creates upside if inventory and receivables normalize, because cash release could improve conversion faster than peers with already leaner cycles.

Overall Score

SXT’s forward positioning is supported by strong liquidity and manageable leverage versus peers, while working-capital intensity and only moderate coverage remain the main constraints.